Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTX-200 with Chemotherapy in Breast Cancer
NCT01697293Phase 2Terminated
- Sponsor
- Prescient Therapeutics
- Start
- Jan 2012
- Primary completion
- Jun 2020
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of triciribine in breast cancer, sponsored by Prescient Therapeutics. Started Jan 2012; status: terminated.
02
Drugs
triciribine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01697293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01697293.